rs587776802

Variant summary

Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PM4PP5_Moderate

The NM_006218.4(PIK3CA):​c.3203dup​(p.Asn1068LysfsTer5) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. L1067L) has been classified as Likely benign.

Frequency

Genomes: not found (cov: 32)

Consequence

PIK3CA
NM_006218.4 frameshift

Scores

Not classified

Clinical Significance

Likely pathogenic criteria provided, single submitter P:3

Conservation

PhyloP100: 8.85
Variant links:
Genes affected
PIK3CA (HGNC:8975): (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 6 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PM4
Frameshift in the end of transcript resulting in stoplost. Downstream stopcodon found after 1204 codons.
PP5
Variant 3-179234358-G-GA is Pathogenic according to our data. Variant chr3-179234358-G-GA is described in ClinVar as [Likely_pathogenic]. Clinvar id is 13658.Status of the report is criteria_provided_single_submitter, 1 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
PIK3CANM_006218.4 linkuse as main transcriptc.3203dup p.Asn1068LysfsTer5 frameshift_variant 21/21 ENST00000263967.4
PIK3CAXM_006713658.5 linkuse as main transcriptc.3203dup p.Asn1068LysfsTer5 frameshift_variant 21/21

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
PIK3CAENST00000263967.4 linkuse as main transcriptc.3203dup p.Asn1068LysfsTer5 frameshift_variant 21/212 NM_006218.4 P1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
31
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

PIK3CA related overgrowth syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingClinical Genomics Laboratory, Washington University in St. LouisAug 21, 2023The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant was identified at an allelic fraction consistent with somatic origin. This variant has been reported in individuals with lung, breast, liver, and bladder cancers (Youssef O et al., PMID: 2819998; Miron A et al., PMID: 20551053; Cizkova Met al., PMID: 22330809; Kachrilas S et al., PMID: 30941989); however, to our knowledge, this variant has not been reported in individuals affected with PIK3CA-Related Overgrowth Spectrum (PROS) disorders. This variant has been reported in multiple cases in the cancer database COSMIC (Genomic Mutation ID: COSV55878665). The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant is absent from the general population (gnomAD v.2.1.1), indicating it is not a common variant. The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant resides within the C-terminal chain, A1052-A1068, of PIK3CA. This variant results in increased cell proliferation, migration, and Akt phosphorylation compared to wild-type gene product and increased transformation ability in several different cell lines in culture (Jin N et al., PMID: 34779417; Ng PK et al., PMID: 29533785). This variant causes a frameshift by duplicating a single nucleotide; however, because this occurs in the last exon, this is not predicted to lead to nonsense-mediated decay. A large number of PI3K/AKT pathway inhibitors are currently under clinical study in both PROS disorders and cancer (Jin N et al., PMID: 34779417; Venot Q et al., PMID: 29899452; Parker VER et al., PMID: 30270358). Based on an internally-developed protocol informed by the ACMG/AMP guidelines (Richards S et al., PMID: 25741868) and gene-specific practices from the ClinGen Criteria Specification Registry, the PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant is classified as likely pathogenic. -
Gastric cancer Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMFeb 17, 2005- -
Hepatocellular carcinoma Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMFeb 17, 2005- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs587776802; hg19: chr3-178952146; API